Clearside Biomedical Shares Rise After Phase 2B Trial of Potential Eye Degeneration Treatment Shows Positive Data

MT Newswires Live10-09

Clearside Biomedical (CLSD) shares were up more than 26% in Wednesday's premarket activity after the company said its topline data from its phase 2b clinical trial of CLS-AX for the treatment of neovascular age-related macular degeneration showed the drug achieved both primary and secondary outcomes.

Among 60 participants in the trial who received CLS-AX, best corrected visual acuity and ocular anatomy were stable for up to six months compared to participants who received the drug aflibercept, the company said.

CLS-AX also showed a "well-tolerated" safety profile at week 36.

Clearside President and Chief Executive George Lasezkay said the results support advancing tests of the drug into phase 3 development.

Age-related macular degeneration causes a loss of central vision and is the most common cause of legal blindness in those over 55 years old.

Price: 1.8700, Change: +0.39, Percent Change: +26.35

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474245688?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-09 19:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2474245688","market":"sg","top_or_hot":-1,"title":"Clearside Biomedical Shares Rise After Phase 2B Trial of Potential Eye Degeneration Treatment Shows Positive Data","media":"MT Newswires Live","content":"<html><body><p> Clearside Biomedical (CLSD) shares were up more than 26% in Wednesday's premarket activity after the company said its topline data from its phase 2b clinical trial of CLS-AX for the treatment of neovascular age-related macular degeneration showed the drug achieved both primary and secondary outcomes.</p><p>Among 60 participants in the trial who received CLS-AX, best corrected visual acuity and ocular anatomy were stable for up to six months compared to participants who received the drug aflibercept, the company said.</p><p>CLS-AX also showed a \"well-tolerated\" safety profile at week 36.</p><p>Clearside President and Chief Executive George Lasezkay said the results support advancing tests of the drug into phase 3 development.</p><p>Age-related macular degeneration causes a loss of central vision and is the most common cause of legal blindness in those over 55 years old.</p><p>Price: 1.8700, Change: +0.39, Percent Change: +26.35</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clearside Biomedical Shares Rise After Phase 2B Trial of Potential Eye Degeneration Treatment Shows Positive Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClearside Biomedical Shares Rise After Phase 2B Trial of Potential Eye Degeneration Treatment Shows Positive Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-09 19:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Clearside Biomedical (CLSD) shares were up more than 26% in Wednesday's premarket activity after the company said its topline data from its phase 2b clinical trial of CLS-AX for the treatment of ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLSD","symbol_name":"Clearside Biomedical Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2474245688","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474245688","pubTimestamp":1728472587,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Clearside Biomedical  shares were up more than 26% in Wednesday's premarket activity after the company said its topline data from its phase 2b clinical trial of CLS-AX for the treatment of neovascular age-related macular degeneration showed the drug achieved both primary and secondary outcomes.Among 60 participants in the trial who received CLS-AX, best corrected visual acuity and ocular anatomy were stable for up to six months compared to participants who received the drug aflibercept, the company said.CLS-AX also showed a \"well-tolerated\" safety profile at week 36.Clearside President and Chief Executive George Lasezkay said the results support advancing tests of the drug into phase 3 development.Age-related macular degeneration causes a loss of central vision and is the most common cause of legal blindness in those over 55 years old.Price: 1.8700, Change: +0.39, Percent Change: +26.35","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLSD":"Clearside Biomedical Inc.","BK4007":"制药"},"translate_title":"潜在眼部退化治疗2B期试验显示积极数据后，Clearside Biomedical股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLSD":1},"content_text":"Clearside Biomedical (CLSD) shares were up more than 26% in Wednesday's premarket activity after the company said its topline data from its phase 2b clinical trial of CLS-AX for the treatment of neovascular age-related macular degeneration showed the drug achieved both primary and secondary outcomes.Among 60 participants in the trial who received CLS-AX, best corrected visual acuity and ocular anatomy were stable for up to six months compared to participants who received the drug aflibercept, the company said.CLS-AX also showed a \"well-tolerated\" safety profile at week 36.Clearside President and Chief Executive George Lasezkay said the results support advancing tests of the drug into phase 3 development.Age-related macular degeneration causes a loss of central vision and is the most common cause of legal blindness in those over 55 years old.Price: 1.8700, Change: +0.39, Percent Change: +26.35","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474245688"}